There is a pressing need for anti-viral agents that are effective against multiple classes of viruses. Broad specificity might be achieved by targeting phospholipids that are widely expressed on infected host cells or viral envelopes. We reasoned that events occurring during virus replication (e.g. cell activation or pre-apoptotic changes) would trigger the exposure of normally-intracellular anionic phospholipids on the outer surface of virus-infected cells. A chimeric antibody, bavituximab, was used to identify and target the exposed anionic phospholipids. Infection of cells with Pichinde virus (a model for Lassa fever virus, a potential bioterrorism agent) led to the exposure of anionic phospholipids. Bavituximab treatment cured overt disease in guinea pigs lethally infected with Pichinde virus. Direct clearance of infectious virus from the blood and antibody-dependent cellular cytotoxicity of virus-infected cells appeared to be the major anti-viral mechanisms. Combination therapy with bavituximab and ribavirin was more effective than either drug alone. Bavituximab also bound to cells infected with multiple other viruses and rescued mice with lethal murine cytomegalovirus infections. Targeting exposed anionic phospholipids with bavituximab appears to be safe and effective. Our study demonstrates that anionic phospholipids on infected host cells and virions may provide a novel target for the generation of anti-viral agents.
Phosphatidylserine (PS), the most abundant anionic phospholipid of the plasma membrane, is segregated to the inner leaflet of the plasma membrane of resting mammalian cells1,2
. This internal positioning of PS is maintained by ATP-dependent aminophospholipid translocases that catalyze aminophospholipid transport from the external to the internal leaflet of the plasma membrane3
. Loss of PS asymmetry occurs during apoptosis, cell injury, cell activation, and malignant transformation4
, and results from inhibition of the translocases or activation of PS exporters, or lipid scrambling enzymes, such as scramblases5,6
Two lines of reasoning lead us to hypothesize that exposure of PS and possibly other anionic phospholipids would commonly occur on the surface of virus infected cells. First, viruses, including herpesviruses, Hepatitis C, HIV-1, Pichinde, Machupo and vaccinia, activate host cells to replicate efficiently7–10
. Virus-induced cell activation may lead to rises in intracellular Ca2+
that, in turn, cause PS externalization by activating PS exporters and inhibiting PS import by translocases4
. This prediction should apply to both enveloped and non-enveloped viruses. Second, PS translocation to the external host cell surface could be an early event associated with virus-induced apoptosis, as occurs with influenza A11
and vaccinia viruses14
To detect and target exposed anionic phospholipids, we used a mouse monoclonal IgG3
antibody, 3G4, which binds with high affinity to complexes of the PS-binding plasma protein β2
-glycoprotein I (β2
GP1) and anionic phospholipids15
. The antibody binds to PS-expressing membranes by crosslinking two molecules of β2
GP1 bound to PS on the membrane16
. The 3G4-β2
GP1-PS complex is only stably formed on PS surfaces. A chimeric version of 3G4, bavituximab, has been generated having mouse 3G4 VH
domains joined to human IgG1 κ constant domains.
Pichinde is an arenavirus that causes lethal hemorrhagic fever in guinea pigs, closely resembling Lassa fever17
in man. We first determined whether infection of P388D1 cells by Pichinde virus induces PS exposure on the cell surface by flow cytometry. Anionic phospholipids began to appear on the cell surface 6 h after infection, at about the same time as viral antigens, and became progressively stronger over 72 h (). Immunofluorescence microscopy showed Pichinde infection induces a faint, diffuse plasma membrane staining together with intensely stained discrete regions resembling membrane blebs ( and Supplementary Fig. 1
online). Next, we determined whether Pichinde virions carry external PS on their envelopes. Virus suspensions were incubated with ELISA plates coated with bavituximab or control Ig. Selective binding to bavituximab-coated pates was observed (). Bead depletion studies established that bavituximab binds to infectious virions. Bavituximab-coated magnetic beads specifically removed infectious Pichinde virus, confirming that infectious virions carry external PS ().
Bavituximab binds to Pichinde virus-infected cells and to infectious virions
The therapeutic activity of bavituximab was determined in guinea pigs with advanced Pichinde virus infections. Outbred guinea pigs were treated with bavituximab or isotype-matched control antibody 6–7 d after infection, when the guinea pigs displayed loss of body weight, ruffled fur, and elevated body temperature. All guinea pigs in the control groups had to be euthanatized by day 14–18. In contrast, 50% of the bavituximab-treated guinea pigs recovered. They gained weight and within a week lacked physical signs of disease, and were healthy on day 135 when the experiments were terminated (). This is the first report of a therapeutic effective against advanced Pichinde virus infections. 14 d after infection, virus loads decreased in blood, spleen, lung, liver, kidney and heart from bavituximab-treated guinea pigs compared to control Ig-treated animals (). Decreases in virus load were not seen before day 14 (Supplementary Fig. 2
online). By day 135, the bavituximab-treated survivors had completely cleared virus from their tissues (not shown). Combining bavituximab and ribavirin (the drug of choice for treating Lassa fever) had additive activity, as expected for drugs with non-overlapping mechanisms of action. With the combined treatment, 63% of guinea pigs survived, compared to 39% and 35% of animals treated with ribavirin or bavituximab alone, respectively ().
Therapeutic effect against Pichinde virus in lethally infected guinea pigs displaying overt signs of disease
The protective effect of bavituximab does not appear to be due to direct neutralization. Bavituximab only inhibits Pichinde-virus replication by 60% in virus-yield assays in vitro
, even in physiological concentrations of β2
GP1 (Supplementary Fig. 3a
online). Thus, PS on Pichinde virus may not be required for virus entry, in contrast to vaccinia14
where viral PS is required for infectivity14
. Also, protection is not due to induction of neutralizing antibodies to Pichinde virus ( and Supplementary Fig. 4a
online) or Pichinde virus specific T-cells ( and Supplementary Fig. 4b
) as neither was detectable 6–7 d after onset of treatment (14 d after infection) when the treated animals begin to recover. Two mechanisms appear to explain the protective effect: 1) bavituximab causes opsonization and clearance of infectious virus from the bloodstream, leaving less virus to infect other tissues. Bavituximab treatment of viremic guinea pigs reduced infectious virus in the bloodstream by 95% within 24 h (); 2) bavituximab induces antibody-dependent cellular cytotoxicity (ADCC) of virus-infected cells. Bavituximab mediates lysis of virus-infected primary guinea pig fibroblasts by primary guinea pig macrophages in vitro
(). Since PS exposure is an early event during virus infection, ADCC may limit virus spread.
Mechanism of anti-viral effects of bavituximab
To explore whether PS exposure is a common feature of virus-infected cells, we tested bavituximab binding to cells infected with influenza A, vaccinia, vesicular stomatitis virus (VSV) and murine CMV. All four viruses induced PS exposure as detected by flow cytometry () or fluorescence microscopy ( and Supplementary Fig. 5
online). This accords with previous studies using annexin V, showing PS externalization on the surface of cells infected with influenza A18
, HIV-112, 19
. Fluorescence microscopy showed that infection induced diffuse staining of the plasma membrane and the formation of membrane blebs, like those on Pichinde virus infected cells ( and Supplementary Fig. 5
Broad spectrum recognition of virus infected cells and protection against cytomegalovirus infection in mice
PS also appears to be commonly exposed on enveloped virions. As with Pichinde virus, we found that bavituximab-coated beads specifically bound to and removed infectious VSV virions from suspensions (Supplementary Fig. 6
online). Others have reported that annexin V binds to the external surface of HIV-119
and vaccinia virus14
. Many non-icosohedral viruses that bud out from the plasma membrane are assembled in, and bud out of, membrane microdomains, commonly called ‘rafts’ 20
, Moloney murine leukemia virus23
, and respiratory syncytial25
viruses all appear to egress from rafts. PS is highly enriched in rafts26
and may stabilize raft formation27
. Co-capping and colocalization studies have demonstrated that PS is present on the outer surface of rafts in activated B-cells28
and activated neutrophils29
. Possibly, in cells activated to expose PS by virus infection, PS likewise becomes incorporated into raft outer surfaces, from where it is assimilated into the outer viral envelope during budding and egress. Also, the herpesviruses, CMV, HSV-1 and HSV-2, which acquire their envelopes from intracellular organelles, have externalized PS30,31
. Herpesviruses obtain their final envelope when they bud into vesicles derived from the trans-Golgi network32
. Perhaps Golgi-associated structures into which the virions bud have not yet developed full lipid asymmetry, or they lose PS asymmetry along with the plasma membrane during virus infection.
Our observation that PS is externalized on CMV-infected cells prompted us to test 3G4 against lethal mCMV infections. Bavituximab does not directly neutralize mCMV in vitro
(Supplementary Fig. 3b
). BALB/c mice were infected with an LD80
dose of mCMV and treated with 3G4 18 h later. Most control mice had to be euthanatized by day five, and only 25% were alive at day 96 (). In contrast, 3G4 treated mice initially lost weight but then recovered and all were alive at day 96 when the experiment was terminated. These results suggest that the protective effect of bavituximab is not unique to Pichinde virus and/or guinea pigs.
Bavituximab therapy appears to be well-tolerated. Treated animals retained normal body weight, appetite, appearance and physical activity. No evidence of toxicity was visible histologically. Coagulation parameters remained within the normal range (Supplementary Fig. 7
online). 3G4 recognizes domain II of β2
GP1, which is not known to be associated with anti-phospholipid syndromes33
. In Phase I clinical studies, bavituximab treatment of patients with chronic hepatitis C infections appeared safe and well tolerated. Reductions in serum HCV RNA levels were observed34,35
PS on virions and virally infected cells may enable viruses to evade immune recognition and dampen inflammatory responses to infection. Viruses may have subverted physiological mechanisms by which apoptotic cells avoid inducing inflammation and autoimmunity. PS suppresses activation and maturation of dendritic cells36
, inhibits inflammatory responses of macrophages37,38
and adaptive immune responses in vivo
. Bavituximab treatment may mask PS on virus-infected cells and/or viruses, leading to the development of effective anti-viral immune responses.
In conclusion, targeting PS on cells infected with multiple different viruses and on virions themselves shows promise as an anti-viral strategy. Because anionic phospholipids on virus-infected cells are host-derived and independent of the viral genome, the acquisition of drug resistance should be less problematic than with agents that target virus-encoded components.